Efficacy and safety of spironolactone in acute heart failure: The ATHENA-HF randomized clinical trial

JAMA Cardiology

Volumn 2, Issue 9, 2017, Pages 950-958

  Butler, Javed ^a   Anstrom, Kevin J ^b   Felker, G Michael ^c   Givertz, Michael M ^d   Kalogeropoulos, Andreas P ^e   Konstam, Marvin A ^f   Mann, Douglas L ^g   Margulies, Kenneth B ^h   McNulty, Steven E ^b   Mentz, Robert J ^c   Redfield, Margaret M ⁱ   Tang, W H Wilson ^j   Whellan, David J ^k   Shah, Monica ^l   Desvigne Nickens, Patrice ^m   Hernandez, Adrian F ^c   Braunwald, Eugene ^d  

^a STONY BROOK UNIVERSITY   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g WASHINGTON UNIVERSITY   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ MAYO CLINIC   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k THOMAS JEFFERSON UNIVERSITY   (United States)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; PLACEBO; POTASSIUM; SPIRONOLACTONE; BRAIN NATRIURETIC PEPTIDE; MINERALOCORTICOID ANTAGONIST; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ESTIMATED GLOMERULAR FILTRATION RATE; ETHNIC DIFFERENCE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; URINE VOLUME; WEIGHT CHANGE; ACUTE DISEASE; BLOOD; DOSE RESPONSE; HEART FAILURE; HEART STROKE VOLUME; MORTALITY; PATHOPHYSIOLOGY;

ACUTE DISEASE; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MORTALITY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SPIRONOLACTONE; STROKE VOLUME;

EID: 85032636181     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2017.2198     Document Type: Article

References (18)

1. Mozaffarian D, Benjamin EJ, Go AS, et al; Writing Group Members; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016; 133(4):447-454.
2. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123-1133.
3. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011;306(15): 1669-1678.
4. Mentz RJ, Stevens SR, DeVore AD, et al. Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. JACC Heart Fail. 2015;3(2):97-107.
5. Abdallah JG, Schrier RW, Edelstein C, Jennings SD, Wyse B, Ellison DH. Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(−)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol. 2001;12(7):1335-1341.
6. Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail. 2009;2(4):370-376.
7. Girerd N, Pang PS, Swedberg K, et al; EVEREST investigators. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. Eur J Heart Fail. 2013;15(11):1228-1235.
8. Hensen J, Abraham WT, Dürr JA, Schrier RW. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol. 1991;11(6):441-446.
9. van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol. 1993;71(3):21A-28A.
10. Sarwar CM, Papadimitriou L, Pitt B, et al. Hyperkalemia in heart failure. J Am Coll Cardiol. 2016;68(14):1575-1589.
11. Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. Eur J Intern Med. 2014;25(1): 67-72.
12. Butler J, Hernandez AF, Anstrom KJ, et al. Rationale and design of the ATHENA-HF Trial: aldosterone targeted neurohormonal combined with natriuresis therapy in heart failure. JACC Heart Fail. 2016;4(9):726-735.
13. Ambrosy AP, Pang PS, Khan S, et al; EVEREST Trial Investigators. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013;34(11):835-843.
14. Lachin JM. Worst-rank score analysis with informatively missing observations in clinical trials. Control Clin Trials. 1999;20(5):408-422.
15. Armanini D, Sabbadin C, Donà G, Clari G, Bordin L. Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs. Expert Opin Pharmacother. 2014;15(7): 909-912.
16. Ziaeian B, Sharma PP, Yu T-C, Johnson KW, Fonarow GC. Factors associated with variations in hospital expenditures for acute heart failure in the United States. Am Heart J. 2015;169(2):282-289.e15.
17. Pitt B, Anker SD, Böhm M, et al. Rationale and design of Mineralocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015;17(2):224-232.
18. Chen HH, Anstrom KJ, Givertz MM, et al; NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013;310(23): 2533-2543.